|
PPP2R5D expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.04700004222025E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.22650000156099E-08 |
| Normal-vs-Stage2 |
1.657990E-01 |
| Normal-vs-Stage3 |
5.7432000266644E-09 |
| Normal-vs-Stage4 |
5.85259996022103E-09 |
| Stage1-vs-Stage2 |
6.338500E-03 |
| Stage1-vs-Stage3 |
3.384200E-01 |
| Stage1-vs-Stage4 |
1.864030E-01 |
| Stage2-vs-Stage3 |
1.580230E-03 |
| Stage2-vs-Stage4 |
1.138290E-03 |
| Stage3-vs-Stage4 |
6.400200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.08969960727268E-10 |
| Normal-vs-AfricanAmerican |
5.370100E-02 |
| Normal-vs-Asian |
4.03609999999333E-06 |
| Caucasian-vs-AfricanAmerican |
4.845800E-02 |
| Caucasian-vs-Asian |
3.190800E-01 |
| AfricanAmerican-vs-Asian |
2.154400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.91600999999153E-05 |
| Normal-vs-Female |
5.66140023749995E-10 |
| Male-vs-Female |
1.913380E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.62230000439112E-08 |
| Normal-vs-Age(41-60Yrs) |
1.30790001051651E-09 |
| Normal-vs-Age(61-80Yrs) |
2.28179999999245E-05 |
| Normal-vs-Age(81-100Yrs) |
6.229800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.957400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.579200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.319600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.809570E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.076800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.666800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.627680E-02 |
| Classical-VS-Follicular |
9.916600E-03 |
| Classical-VS-Other |
9.854800E-01 |
| Classical-VS-Normal |
1.82830000028389E-08 |
| Tall-VS-Follicular |
2.419500E-04 |
| Tall-VS-Other |
4.508000E-01 |
| Tall-VS-Normal |
1.14059994782423E-09 |
| Follicular-VS-Other |
4.397600E-01 |
| Follicular-VS-Normal |
2.740400E-03 |
| Other-VS-Normal |
1.499520E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.4371000000013E-06 |
| Normal-vs-N1 |
5.98410210272959E-14 |
| N0-vs-N1 |
1.42250000001454E-06 |
|
|
